BOSTON – April 16, 2025 – PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal transformer (PLUTO) foundation model and portfolio of oncology products at the American Association of Cancer Research (AACR) Annual Meeting being held from April 25-30, 2025, in Chicago, IL.
The data to be presented demonstrate the power of PathAI’s pathology universal transformer (PLUTO) foundation model to anchor models that predict oncogenic molecular driver alterations from routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs). These presentations also highlight PathExplore 1, PathAI’s AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) with single-cell resolution.These novel findings illustrate the potential of PathAI’s AI models to facilitate screening of patient samples for clinical trials.
Poster Details
Session: Artificial Intelligence for Digital Pathology and Spatial Molecular Technologies
Section: 45
Title: AI-powered approaches accurately predict t(11;14) positive multiple myeloma from H&E-stained histologic sections by identifying regions demonstrating lymphoplasmacytic cytology (Abstract Number 2425 / 10)
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.
Footnote
1 PathExplore is For Research Use Only. Not for use in diagnostic procedures.
The data to be presented demonstrate the power of PathAI’s pathology universal transformer (PLUTO) foundation model to anchor models that predict oncogenic molecular driver alterations from routine hematoxylin and eosin (H&E)-stained whole slide images (WSIs). These presentations also highlight PathExplore 1, PathAI’s AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) with single-cell resolution.These novel findings illustrate the potential of PathAI’s AI models to facilitate screening of patient samples for clinical trials.
Poster Details
Session: Artificial Intelligence for Digital Pathology and Spatial Molecular Technologies
Section: 45
Title: AI-powered approaches accurately predict t(11;14) positive multiple myeloma from H&E-stained histologic sections by identifying regions demonstrating lymphoplasmacytic cytology (Abstract Number 2425 / 10)
- Presenter: Lara Murray, Ph.D., Senior Translational Science Lead, PathAI
- Date and Time: Monday, April 28, 2025, from 9:00 a.m. – 12:00 p.m. CT
- Presenter: Ylaine Gerardin, Ph.D., Principal Biomedical Data Scientist, PathAI
- Date and Time: Monday, April 28, 2025, from 9:00 a.m. – 12:00 p.m. CT
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.
Footnote
1 PathExplore is For Research Use Only. Not for use in diagnostic procedures.
